● Recruiting

Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration

Condition: Age Related Macular Degeneration · Exudative Age-Related Macular Degeneration · Anti Vascular Endothelial Growth Factor · Sponsor: Saglik Bilimleri Universitesi

PhaseN/A

Planned participants54

Who can joinAll sexes, 45 Years to 90 Years

Healthy volunteersNo

About this study

In this study, patients receiving Eylea treatment will be treated with Yesafili, a biosimilar molecule, and routine examination results will be noted.

This description comes directly from the study's public registry record.

Talk to the study team

Sinan Kalpakoğlu, M.D. · +905380518244 · sinankalpakoglu17@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Prof. Dr. Cemil Taşcıoğlu City Hospital

Istanbul, şişli, Turkey (Türkiye)

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07235527